FLNAHIGH SIGNALFINANCIAL10-K

FLNA shows substantially improved operating cash flow and meaningfully reduced R&D expenses, but with a significant decline in stockholders' equity and overall asset base.

The company appears to be in a cash conservation phase, with research and development expenses substantially reduced compared to the prior year. While operating cash flow improved meaningfully, the decline in stockholders' equity and total assets suggests the company is burning through its capital base, which could signal financial stress or a strategic pivot away from intensive R&D activities.

Comparing 2026-03-12 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

FLNA's financial position reflects a company in transition, with operating cash flow improving substantially while R&D expenses were meaningfully reduced. The company's asset base contracted notably, with cash and equivalents declining by over $33 million and stockholders' equity falling by nearly half. This pattern suggests either aggressive cost-cutting measures or completion of a major research phase, though the overall shrinking balance sheet indicates ongoing capital consumption despite improved cash flow metrics.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+72.4%
-$116.9M-$32.3M

Operating cash flow surged 72.4% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-61.8%
$69.6M$26.6M

R&D spending cut 61.8% — could signal cost discipline or concerning reduction in innovation investment.

Stockholders Equity
Balance Sheet
-48.9%
$145.7M$74.4M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
+32.6%
-$141.4M-$95.4M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Assets
Balance Sheet
-28.4%
$136.5M$97.7M

Current assets declined 28.4% — monitor working capital adequacy and short-term liquidity.

Cash & Equivalents
Balance Sheet
-25.7%
$128.6M$95.5M

Cash decreased 25.7% — monitor burn rate and upcoming capital needs.

Total Assets
Balance Sheet
-24.9%
$157.5M$118.4M

Total assets contracted 24.9% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-03
ADDED
false --12-31 FY 2025 true true true false Our Director of Information Technology has responsibilities which include preventing and monitoring cybersecurity threats and utilizes the assistance of external vendors in this effort.
Our Director of Information Technology regularly reports to senior management regarding the status of our cybersecurity program, emerging cybersecurity threats, long-term cybersecurity investments and strategies, and oversight of our cybersecurity profile.
Our Director of Information Technology has responsibilities which include preventing and monitoring cybersecurity threats and utilizes the assistance of external vendors in this effort.
Our Director of Information Technology regularly reports to senior management regarding the status of our cybersecurity program, emerging cybersecurity threats, long-term cybersecurity investments and strategies, and oversight of our cybersecurity profile.
true Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks.
+7 more — sign up free →
REMOVED
sava20241231c_10k.htm 0001069530 CASSAVA SCIENCES INC false --12-31 FY 2024 true true false true Our full Board of Directors oversees the risk management process for the Company, which includes identifying, assessing and managing enterprise-level risks.
0.001 0.001 10,000,000 10,000,000 0 0 0 0 0.001 0.001 120,000,000 120,000,000 48,203,179 48,203,179 42,236,919 42,236,919 0 http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense 0 1 4 2 0 10 0 0 0 4.3 0 0 0 0 21 0 2020 2021 2022 2023 2024 4 4 1 4 2 1 1 3 2 2 4 16.9 1.5 0.1 0 0 0 0 0 0 false false false false Other segment items include interest income, other income, net and gain from change in fair value of warrant liabilities.
All statements other than statements of present or historical facts contained in this Annual Report, including statements anticipating or otherwise relating to our future results of operations and financial position, future results of clinical trials, business strategy, plans and objectives for future operations, and anticipated events or trends, are forward-looking statements.
In some cases, forward-looking statements are identified by terms such as aim, anticipate, believe, could, drive, estimate, expect, forecast, future, goal, intend, may, objective, plan, potential, project, seek, should, strategy, will and would or the negatives of these terms or other comparable terminology.
government inquiries; and litigation, claims or other uncertainties that may arise from allegations made against us or our former employees or collaborators.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →